Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) pre-open: BUY opportunities post sell-off

March 9, 2021 7:53am

Earnings are still being released

Pre-open indications: 10 BUYs and 1 SELL

News: Ultragenyx Pharmaceutical (RARE) the FDA has approved IND application for UX053, an experimental mRNA therapy designed for the treatment of Glycogen Storage Disease Type III (GSDIII).

Companies mentioned this a.m.: BSTG, AGTC, BLUE, CRSP, EDIT, NTLA

RMi’s daily report may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

Dow futures are UP +0.46% (+145 points), S&P futures are UP +0.98% (+38 points) and NASDAQ futures are UP +2.16% (+266 points)

Dow futures rose are pointing higher in pre-market trading,

European stocks moved modestly higher as the pan-European Stoxx 600 closed up +2.2% on Monday and is positioning early +0.4% during the morning session,

Asia-Pacific stocks were mixed with mainland Chinese shares retreating sharply while Japan’s Nikkei 225 closed +0.99% higher.

Henry’omics:

Although only the Dow was up on Monday, “our universe experienced a shocking downslide yesterday; The small-cap benchmark Russell 2000 gained about 0.5%.

“Investors this week will watch as the U.S. House of Representatives plans to pass a $1.9 trillion coronavirus relief bill to get fresh aid to Americans starting this month. That follows after the Senate passed the legislation over the weekend.” <CNBC>

Monday’s evening’s recap: “very few winners in volatile trading as small cap risks manifested downside momentum, forgotten fundamentals with a lack of rhyme or reason trampling any sector sentiment in today’s session. WAIT, if the Phoenix can rise, although a myth – come-backs are coming.” … https://www.regmedinvestors.com/articles/11801

The Nasdaq closed DOWN -310.99 points (-2.41%);
The IBB closed down -1.94% and XBI closed down -2.77%;
Sector volume was LOW with 1 of the 3-upside having higher than the 3-month average volume with the volume of 6 of 30-downside having higher than the 3-month average volume;
The CBOE Volatility Index (VVIX: INDEX) was up +1.20 points or +4.87% at 25.96;
Monday’s percentage (%) of the 3-upside were +0.49% (CLLS) to +2.23% (CLBS) while the 30-downside ranges from -0.21% (FIXX) to -10.08% (NTLA);

March: 2 positive, 4 negative closes

February: 9 positive, 10 negative closes and 1 holiday

January: 10 positive, 9 negative closes and 1 holiday

Companies in my headlights – It’s your decision; I provide an idea and context:

Maintaining Sell: Questions continue …

Biostage (BSTG) closed down -$0.03 to $1.60 with 6,196 shares traded (pumped re promoted”) after being flat Friday with 217 shares traded, Thursday’s 2,083 shares being traded, Wednesday’s being flat at $1.63 with 32 shares traded and last Tuesday’s -$0.01 to $1.63 with 275 shares traded. Reiterating

Question#1: Has the principal investigator, Dr. Christine Finck, MD, Connecticut Childrens (hospital) disclosed shares personally owned (?) whose lab was funded by multiple levels of a corporate GIFT, corporate spending and reimbursements from BSTG. BUT the largest issue is … the financial reporting at the end of the IND filing – WAS her stock holdings listed or the CEO’s personal holdings and the hospital’s stock holdings? Shouldn’t or don’t Investigators NOT own shares for many reasons which include issues of transparency that could be considered prejudicial to the “proper” designation of unbiased research role of lead investigators?

Question#2: Doesn’t these issues put MORE governmental, fiduciary and transparency responsibility on the new board and audit committee member, Herman Sanchez and RSM US LLP?

MINORITY shareholders are watching and weighting responses to MAINTAIN their RIGHTS.

BUY:

Applied Genetic Technologies (AGTC) closed down again -$0.22 to $4.66 after Friday’s -$0.18 to $4.88, Thursday’s $5.06, Wednesday’s $5.42 and last Tuesday’s $5.81 with a positive +$0.32 or +6.87% pre-market indication.

Bellicum Pharmaceuticals (BLCM) closed down -$0.01 to $3.68 after Friday’s $3.69 with a positive +0.16 or +4.345 pre-market indication.

bluebird bio (BLUE) closed down -$0.43 to $28.25 after Friday’s up +$0.74 to $28.68 and Thursday’s -$1.40 to $27.94 with a positive +$0.37 or +1.31% pre-market indication.

Cellectis SA (CLLS) closed up +$0.09 to $18.28 after Friday’s $18.19 and last Thursday’s earnings’ release with a positive +$0.73 or +3.99% pre-market indication.

Intellia Therapeutics (NTLA) closed down again -$5.22 to $46.59 after Friday’s -$2.61 to $51.81 and Thursday’s -$3.29 to $54.42 with a positive +$1.911 or +4.10% pre-market indication

CRISPR Therapeutics (CRSP) closed down again -$1.03 to $113.62 after Friday’s -$0.84 to $114.65 with a positive +$5.65 or +4.97% pre-market indication.

Editas Medicine (EDIT) closed up -$1.09 to $40.54 after Friday’s +$1.27 to $41.63 after Thursday’s -$2.77 to $40.36 with a positive +$1.12 or +2.76% pre-market indication.

Fate Therapeutics (FATE) closed down -$4.49 to $79.16 after Friday’s $83.65 with a positive +$0.74 or +0.93% pre-market indication.

Global Blood Therapeutics (GBT) closed down -$2.02 to $38.94 after Friday’s $40.96 with a positive +0.76 or +1.95% pre-market indication.

Sangamo therapeutics (SGMO) closed down -$0.48 to $10.88 after Friday’s $11.36 with a positive +$0.12 or +1.10% aftermarket indication.

The BOTTOM LINE: A tug-of-war is taking place in the sector as investors wait for volatile trading to be in their favor; maybe it’s a “churn” to earn session.

However, I STILL am a “beware Man” whose focus has always been “warning analysis” … earnings’ season is NOT over … my advice, trim and skim … if one can!”

Many talk of horizons; “as I have said last week, my horizon is usually a Friday’s close …”

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.